|
1
|
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.
|
Blood
|
2007
|
5.18
|
|
2
|
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.
|
Lancet
|
2016
|
1.44
|
|
3
|
Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network.
|
Ann Oncol
|
2013
|
1.10
|
|
4
|
High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma.
|
Blood
|
2015
|
0.85
|
|
5
|
Mantle cell lymphoma: biology, clinical presentation, and therapeutic approaches.
|
Am Soc Clin Oncol Educ Book
|
2014
|
0.81
|
|
6
|
Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network.
|
Leuk Lymphoma
|
2011
|
0.81
|
|
7
|
New paradigms in mantle cell lymphoma: is it time to risk-stratify treatment based on the proliferative signature?
|
Clin Cancer Res
|
2014
|
0.81
|
|
8
|
Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma: summary of the 12th annual conference of the European Mantle Cell Lymphoma Network.
|
Leuk Lymphoma
|
2014
|
0.78
|
|
9
|
The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?
|
Haematologica
|
2016
|
0.76
|
|
10
|
Personalized medicine in lymphoma: is it worthwhile? The mantle cell lymphoma experience.
|
Haematologica
|
2015
|
0.75
|
|
11
|
How to treat old MCL patients: one size fits it all?
|
Blood
|
2014
|
0.75
|
|
12
|
Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach?
|
Haematologica
|
2017
|
0.75
|